TABLES
I. Summary Table of Events Used for the Pooled Analysis, Stratified By Trial Category.
2
II. Twenty-Year Event Rates By 5-Year Intervals for Each Endpoint in the Simulation Models.
ACS5 / 10 / 15 / 20 / 25 / 30
DEATH
High-Dose / 8.1% / 17.8% / 31.0% / 47.6% / 66.4% / 83.9%
Conventional / 9.3% / 19.3% / 32.7% / 49.4% / 68.2% / 85.2%
MI
High-Dose / 9.8% / 14.5% / 18.7% / 22.1% / 24.5% / 25.9%
Conventional / 11.0% / 16.7% / 21.8% / 25.8% / 28.7% / 30.3%
STROKE
High-Dose / 2.7% / 5.2% / 7.4% / 9.2% / 10.5% / 11.2%
Conventional / 3.2% / 6.2% / 8.9% / 11.0% / 12.5% / 13.3%
REHOSPITALIZATION
High-Dose / 6.7% / 10.5% / 13.9% / 16.7% / 18.6% / 19.8%
Conventional / 7.8% / 12.4% / 16.4% / 19.6% / 21.9% / 23.2%
REVASCULARIZATION
High-Dose / 17.8% / 29.2% / 39.1% / 47.1% / 52.9% / 56.3%
Conventional / 21.2% / 35.7% / 48.3% / 58.4% / 65.7% / 69.8%
CAD
5 / 10 / 15 / 20 / 25 / 30
DEATH
High-Dose / 6.7% / 16.2% / 28.9% / 45.2% / 64.1% / 82.0%
Conventional / 6.8% / 16.3% / 29.1% / 45.5% / 64.4% / 82.3%
MI
High-Dose / 5.3% / 10.1% / 14.4% / 17.9% / 20.5% / 22.0%
Conventional / 6.5% / 12.5% / 17.7% / 22.0% / 25.1% / 27.0%
STROKE
High-Dose / 2.8% / 5.3% / 7.6% / 9.4% / 10.8% / 11.6%
Conventional / 3.4% / 6.5% / 9.3% / 11.5% / 13.2% / 14.1%
REHOSPITALIZATION
High-Dose / 4.3% / 8.2% / 11.7% / 14.5% / 16.6% / 17.8%
Conventional / 5.2% / 9.9% / 14.1% / 17.5% / 20.0% / 21.4%
REVASCULARIZATION
High-Dose / 12.5% / 24.1% / 34.3% / 42.6% / 48.7% / 52.3%
Conventional / 16.3% / 31.3% / 44.4% / 55.2% / 63.0% / 8.4%
III. Summary Table of One-Way Sensitivity Analyses Assuming Statin Efficacy of 50% Beyond 5 Years. Dollar amounts are in 2005 US dollars and are per quality-adjusted life-year.
Intensive statin cost ($1,040-$1,720) / $4,400 to $34,500 / Dominant** to $142,200
Moderate statin cost ($650-$1,090) / $9,900 to $29,000 / Dominant** to $235,100
Baseline annual risk
All-cause mortality* / ---- / ----
Myocardial infarction* / ---- / $62,000 to $75,600
Stroke* / ---- / $59,700 to $79,100
Revascularization* / ---- / $63,400 to $73,000
Rehospitalization* / ---- / -----
Risk ratio with intensive statin
All-cause mortality* / $13,800 to $49,500 / $25,600 to Dominated***
Myocardial infarction* / $17,900 to $20,500 / $59,700 to $74,300
Stroke* / $17,900 to $21,200 / $56,800 to $84,300
Revascularization* / $17,800 to $21,100 / $61,800 to $74,600
Rehospitalization* / ----- / -----
Utility
Myocardial infarction (0.81-1.00) / ---- / $52,200 to $103,300
Stroke, mild disability (0.60-1.00) / ---- / $60,900 to $83,200
Stroke, severe disability (0.00-1.00) / ---- / $55,500 to $106,300
Baseline well health (0.90-1.00) / $18,500 to $23,800 / $52,600 to $435,300
Discount rate (0%-5%) / $17,300 to $20,900 / $59,700 to $74,200
* Analyses not shown when net range less than $2,000 per QALY
** A strategy that is dominant is both more effective and less expensive.
*** A strategy that is dominated is both less effective and more expensive.
2